Advancing Cancer Treatment
Innovating Therapies for a Healthier Tomorrow
Subdivisions: Additional Research Portfolio
Infectious Diseases
Expertise and the utilization of Next Generation Sequencing techniques, bioinformatics, and data analysis in relation to communicable diseases, in terms of diagnostic approaches within the research and development sectors. These sectors include both practices in virology and bacteriology, including studies related to Mycobacterium tuberculosis, inclusive of Mycobacteria other than tuberculosis, influenza, HIV, RSV.
Cardiometabolic Diseases
Encompasses a spectrum of conditions that are significant of the relationship/association between cardiovascular health and metabolic processes. Significance to diabetes, type 2 diabetes, obesity, cardiovascular disease (including hypertension, dyslipidemia, atherosclerosis and heart failure). Through the concept of GWAS (Genome wide association studies, to detect SNPs, single nucleotide polymorphisms), inclusive of genetic predisposition and epigenetic analysis, to ascertain who would ideally benefit from targeted therapies
Autoimmune Diseases
The primary investigation of epigenetics (histone modifications, methylation, phosphorylation, ubiquitination) in various categories, namely celiac disease, Rheumatoid arthritis, type I diabetes, Behcet's syndrome, systemic lupus erythematosus
Rare Diseases
Utilizing various platforms for genomic analysis, most notably Whole Exome Sequencing, Transcriptomics, Targeted sequencing and Chromosomal Microarrays.
Neurodegenerative Diseases
Neuroepigenomics is translating discoveries into precision medicine, most notably in the following sectors, namely Parkinsons, Huntington's Disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and limbic predominant age-related TDP-43 encephalopathy (LATE). Additionally, multiple sclerosis (MS) and neuromyelitis optical spectrum disorder (NMOSD), amyotrophic lateral sclerosis (ALS, often known as “Lou Gehrig's disease”) and progressive supranuclear palsy (PSP), inclusive of Creutzfeldt-Jakob disease
Team
Ms. Raashika Adam
Director/CEO
"Servant Leader, Geneticist and Clinical Trialist. With over 17 years of experience as a medical scientist. Therapeutic areas of interest and expertise, emphasis on both communicable and non-communicable diseases, most notably oncology, tuberculosis (in association with HIV), and COVID-19. Integral membership in the Human Genome Organization (HUGO- International, headquartered in Farmington, USA) too, as part of my many accolades. In addition, a Senior Fellowship Member at the United Nations Artificial Intelligence Forum For Developing Nations, headquartered in Geneva, Switzerland. Oncogenexe Biotech prides itself on a multi- faceted approach to Therapeutic Development, Research and Development, inclusive of utilizing various platforms pertaining to Data Analysis
Services
Therapeutic Development
Creating targeted treatments designed to improve patient outcomes and quality of life Protocol TNBC_003 Antibody Drug Conjugate Development (Monoclonal Antibody, cleaved linkage with drug payload) for TNBC, utilizing the EGFR (Epidermal Growth Factor Receptor) and VEGF (Vascoendothelial Growth Factor Pathways)
Clinical Trials
Oncogenexe Biotech’s Clinical Trials service supports the design and execution of oncology-focused studies to evaluate safety, efficacy, and patient outcomes. Protocol_ TNBC_0_001 A multicentre double-blind placebo-based Phase II Interventional trial evaluating the efficacy of Antibody Drug Conjugate BL-B01D1 in association with Gefitinib, an EGFR tyrosine kinase inhibitor (TKI), in participants stricken with Locally/Advanced Metastatic Basal Like Triple Negative Breast Cancer (TNBC), across sites in Southern Africa and Sub-Saharan Africa Protocol_ PDAC_0_001 A multicentre double blind placebo Phase II interventional study evaluating the phosphoinositide 3 kinase (PI3K) pathway in participants stricken Ductal Adenocarcinoma with locally or advanced Pancreatic Cancer, and the noted targeted therapies,Tesalisib in combination with Samotolisib across participants in South Africa Protocol_DIH_0_001 A Multicentre Open Labelled Phase 1 Observational Trial evaluating the genomic alterations (most notably Epidermal Growth Factor Receptor, EGFR) associated within Non-Small Cell lung Cancer, Breast Cancer and Pancreatic Cancer-stricken Participants (Formalin Fixed Paraffin Embedded Solid tumour biopsies), evaluating the TMB (tumour mutational burden) and MSI (microsatellite instability) across participants in Southern Africa
Patient Support
Providing comprehensive care and resources to patients during their treatment journey.
Mentorship Programmes - Medical and Scientific Life Science Fields
Specifically designed for aspiring molecular biology affiliated medical scientists and doctors (in the genetics, microbiology and biochemistry fields)
Testimonials
Contact
- South Africa
- Fourways, 30 Macbeth Ave
- +27-638021461 - Oncogenexe Biotech Pty Ltd
- raashika@oncogenexe.com
- Mon-Fri - 08:00-19:00